Non-Cystic Fibrosis Bronchiectasis Treatment Market to Reach USD 3.5 Bn by 2035 at 5.8% CAGR, Driven by rising disease burden ...
Insmed Incorporated (Nasdaq: INSM), a people-first global biopharmaceutical company striving to deliver therapies to ...
GlobalData on MSN
Insmed receives EC approval for Brinsupri to treat NCFB
Insmed has received approval from the EC for Brinsupri to treat NCFB in patients aged 12 and above with two or more ...
Bronchiectasis hospitalizations have higher mortality and costs than COPD and asthma, with a median stay of 5 days and costs of $50,393. During the COVID-19 pandemic, bronchiectasis hospitalizations ...
Jefferies London Healthcare Conference 2025 November 18, 2025 3:30 AM ESTCompany ParticipantsWilliam Lewis - President, CEO ...
A new study published in The New England Journal of Medicine showed that over a 52-week period, neither carbocisteine nor ...
A study led by the Research Institute of the McGill University Health Center (The Institute) has identified a rare genetic ...
If you’re one of the 35 million people living with a chronic lung disease in the United States, the form of treatment you receive can impact your health outcomes ...
The George Soros protege has generated legendary returns for decades, so it's hard not to take stock in where Druckenmiller ...
THESE are the four major signs of a common condition which is likely to be triggered by cold weather – and when you should ...
Incorporated announced that the European Commission has approved BRINSUPR for the treatment of non-cystic fibrosis bronchiectasis in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback